TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02538185

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NanoJect device (DebioJect™)
Description: The investigational device used in this study is the NanoJect™ device developed by Debiotech company.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NanoJect device (DebioJect™)
Description: The investigational device used in this study is the NanoJect™ device developed by Debiotech company.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NanoJect device (DebioJect™)
Description: The investigational device used in this study is the NanoJect™ device developed by Debiotech company.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)
Description: The comparator device used for standard ID injections is a classical syringe (1mL BD Luer-Lock™) with a 25G needle (Terumo® Neolus)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)
Description: The comparator device used for standard ID injections is a classical syringe (1mL BD Luer-Lock™) with a 25G needle (Terumo® Neolus)
Study: NCT02495597

Intervention type: OTHER
Intervention: no intervention - just observational
Study: NCT03139578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control 9.0BC
Description: narafilcon A contact lenses with 9.0 base curve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control 9.0BC
Description: narafilcon A contact lenses with 9.0 base curve
Study: NCT04061564

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagal nerve stimulation
Description: The participant will be administered electrical stimulation at a level specifically set to their comfort. This will be performed using a TENS machine device.
Study: NCT02538185

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)
Description: The comparator device used for standard ID injections is a classical syringe (1mL BD Luer-Lock™) with a 25G needle (Terumo® Neolus)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
Description: The comparator device used for standard IM injections is a classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
Description: The comparator device used for standard IM injections is a classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
Description: The comparator device used for standard IM injections is a classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaccin rabique Pasteur®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaccin rabique Pasteur®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaccin rabique Pasteur®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride (NaCl) 0,9%; B. Braun

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride (NaCl) 0,9%; B. Braun

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride (NaCl) 0,9%; B. Braun
Study: NCT02526654

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heidelberg Edge Perimeter
Description: HEP measures peripheral vision

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heidelberg Edge Perimeter
Description: HEP measures peripheral vision

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Octopus Visual Field
Description: OVF measures peripheral vision

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Octopus Visual Field
Description: OVF measures peripheral vision
Study: NCT03139578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control 9.0BC
Description: narafilcon A contact lenses with 9.0 base curve
Study: NCT04061564

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vagal nerve stimulation
Description: The participant will be administered electrical stimulation at a level specifically set to their comfort. This will be performed using a TENS machine device.
Study: NCT00557882

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: synthetic polypropylene mesh
Description: Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: synthetic polypropylene mesh
Description: Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.
Study: NCT01931475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT00968643

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Given in multiple fractions or as a single fraction
Study: NCT01314755

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IMPACT
Description: IMPACT (Nestlé Healthcare Nutrition, Minnetonka, MN, USA) an 'immune-enhancing' feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: An iso-caloric, iso-nitrogenous control feed
Study: NCT04203706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofunctional imaging
Description: Subjects will be submitted to a functional neuroimaging scanning procedure
Study: NCT02933983

Intervention type: OTHER
Intervention: no intervention, compare URT microbiome healthy control group-chronic rhinosinusitis patients

Intervention type: OTHER
Intervention: no intervention, compare URT microbiome healthy control group-chronic rhinosinusitis patients
Study: NCT00735683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATHX-105 phosphate
Description: includes diet, physical activity, and lifestyle modification

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATHX-105 phosphate
Description: includes diet, physical activity, and lifestyle modification

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATHX-105 phosphate
Description: includes diet, physical activity, and lifestyle modification

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATHX-105 phosphate
Description: includes diet, physical activity, and lifestyle modification

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATHX-105 phosphate
Description: includes diet, physical activity, and lifestyle modification
Study: NCT02526654

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: OCT measures retinal nerve fiber layer thickness

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: OCT measures retinal nerve fiber layer thickness
Study: NCT00968643

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Given in multiple fractions or as a single fraction
Study: NCT00735683

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: includes diet, physical activity, and lifestyle modification
Study: NCT04398589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: We used 9.5 ml of 0.75% ropivacaine and 0.5 ml (50 μg) of dexmedetomidine each for preemptive suprascapular nerve block and axillary nerve block just before arthroscopic repair of rotator cuff tear.
Study: NCT03983512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PULSTA TPV System
Description: PULSTA transcatheter pulmonary valve replacement.
Study: NCT04412044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab Injection [Nucala]
Description: Patients receive monthly injection with 100 mg mepolizumab
Study: NCT04398589

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: We used 9.5 ml of 0.75% ropivacaine and 0.5 ml normal saline each for preemptive suprascapular nerve block and axillary nerve block just before arthroscopic repair of rotator cuff tear.
Study: NCT00589758

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: 2D and 3D echocardiography

Intervention type: OTHER
Intervention: Biomarker evaluation
Description: Blood and urine collected
Study: NCT01164995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1775 and carboplatin
Description: Carboplatin will be administered in a dose resulting in AUC5 (i.v. 30 min) at day 1 of each cycle. Concomittantly with the start of the carboplatin infusion 225 mg of MK-1775 will be administered as an oral capsule, followed by 4 additional doses at 12 hour increments ( = 5 BID doses of MK-1775 in 2.5 days in total). One cycle will last 21 days.
Study: NCT01164033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO5045337
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5045337
Description: single oral dose
Study: NCT04401267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive Antihypertensive Therapy
Description: Receives intensive antihypertensive therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Antihypertensive Therapy
Description: Receives conventional antihypertensive therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Survey
Description: The symptom survey is comprised of the PROMIS Ped 25 profile, PROMIS pain interference 8a, PROMIS physical activity 8a, and PROMIS mobility 8a during induction (day 23-28), during week 17 of continuation (+/- 2 weeks), and continuation week 49 (+/- 3 weeks).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom Survey
Description: The symptom survey is comprised of the PROMIS Ped 25 profile, PROMIS pain interference 8a, PROMIS physical activity 8a, and PROMIS mobility 8a during induction (day 23-28), during week 17 of continuation (+/- 2 weeks), and continuation week 49 (+/- 3 weeks).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semi-structured interview
Description: Patients will be interviewed by a trained examiner about their treatment and symptom burden on Week 49 of TOT17 Continuation Therapy. The interview will be recorded and will take about 30-45 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-structured interview
Description: Patients will be interviewed by a trained examiner about their treatment and symptom burden on Week 49 of TOT17 Continuation Therapy. The interview will be recorded and will take about 30-45 minutes.
Study: NCT02742948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: IV ceftriaxone (2g) will be given to all participants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: IV ceftriaxone (2g) will be given to all participants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: IV ceftriaxone (2g) will be given to all participants
Study: NCT02246127

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Everolimus
Description: 10mg/daily, oral. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Everolimus
Description: 10mg/daily, oral. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STZ-5FU
Description: 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-5 every 6 weeks (Moertel) or 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-3, and then 1 day with 1g/m2 and 1 day 400mg/m2 5-FU every 3 weeks (Uppsala).~Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STZ-5FU
Description: 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-5 every 6 weeks (Moertel) or 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-3, and then 1 day with 1g/m2 and 1 day 400mg/m2 5-FU every 3 weeks (Uppsala).~Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT01628029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo CBT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo CBT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo CBT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo CBT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo CBT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo CBT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo CBT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo CBT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Undergo light therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Undergo light therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Undergo light therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Undergo light therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO
Study: NCT01164033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5045337
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5045337
Description: single oral dose
Study: NCT01628029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00955032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Frequency Repetitive Transcranial Magnetic Stimulation
Description: In patients randomized to receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz). We will administer rTMS trains every 30 seconds for 25 minutes. Stimulus intensity for the first and second trains will be 80 and 90% of MEP threshold, respectively.
Study: NCT01628029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00955032

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation
Description: Patients randomized to receive sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
Study: NCT01628029

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Intervention
Description: Undergo sham light therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Intervention
Description: Undergo sham light therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Intervention
Description: Undergo sham light therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Intervention
Description: Undergo sham light therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Melatonin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Melatonin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Melatonin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Melatonin
Description: Given PO
Study: NCT03900468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa™ PC and Percept™ PC Neurostimulation Systems
Description: Implanted DBS system consisting of a Neurostimulator, Leads, Extensions, and potential accessories including Burr Hole Devices, Clinician Tablet, Clinician Programmer Therapy Application Software, Clinician Programmer Communicator, Patient Programmer
Study: NCT04319211

Intervention type: OTHER
Intervention: Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.
Description: The study will include those who isolate themselves at home for fear of contracting Coronavirus disease or suspected of having it. The last three sections of the International Physical Activity Questionnaire (IPAQ) will be used to evaluate the current physical activity level of the participants. Parameters such as housework, home care and family care, rest, sports and leisure physical activities, sitting time will be evaluated. Short Form 12 (Short Form12- SF12) quality of life scale will be used to evaluate health-related quality of life. Beck Depression Scale will be applied to investigate the stress levels of the individuals participating in our study.
Study: NCT01292954

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberries
Description: low dose: 31.4 g of freeze dried blueberry reconstituted in water medium dose: 57 g of freeze dried blueberry reconstituted in water high dose: 80 g of freeze dried blueberry reconstituted in water Placebo: sugars and vitamin c match control in water Frequency:1 single time Total Duration: 3 days study over 3 weeks period

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Blueberries
Description: low dose: 31.4 g of freeze dried blueberry reconstituted in water medium dose: 57 g of freeze dried blueberry reconstituted in water high dose: 80 g of freeze dried blueberry reconstituted in water Placebo: sugars and vitamin c match control in water Frequency:1 single time Total Duration: 3 days study over 3 weeks period

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberries
Description: low dose: 31.4 g of freeze dried blueberry reconstituted in water medium dose: 57 g of freeze dried blueberry reconstituted in water high dose: 80 g of freeze dried blueberry reconstituted in water Placebo: sugars and vitamin c match control in water Frequency:1 single time Total Duration: 3 days study over 3 weeks period

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberries
Description: low dose: 31.4 g of freeze dried blueberry reconstituted in water medium dose: 57 g of freeze dried blueberry reconstituted in water high dose: 80 g of freeze dried blueberry reconstituted in water Placebo: sugars and vitamin c match control in water Frequency:1 single time Total Duration: 3 days study over 3 weeks period
Study: NCT04199858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline pain stimulations
Description: During baseline pain stimulations, a comparison block will include 6 high- and 2 moderate-pain stimulations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditioning
Description: During nocebo induction trials, the conditioned stimulus (i.e., a sham medical gel that can increase pain sensitivity, named TDA and contained in either a brown or a blue jar) is paired to unconditioned high-pain stimuli (nocebo trials). Lower 'baseline' pain is paired with no gel application (control trials).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evocation
Description: During nocebo evocation, lower pain stimulations are administered both after the administration of the conditioned stimulus (i.e., a sham medical gel TDA) and the control stimulus (no medical gel), in order to evoke nocebo responses to the sham hyperalgesic medication.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Description: In the single group of participants, EEG recordings will be conducted during baseline, during a first resting-state of 5-minutes, during induction/evocation of nocebo responses, and during a second resting-state of 5-minutes.